Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8478967 | 0.91 | TACR1 (0.40) | ALDH1A1AGTR2 | |
| SCHEMBL7573297 | 0.87 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1LMNA | |
| SCHEMBL13567995 | 0.87 | L3MBTL1 (0.46) | SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3916786 | 0.84 | AGTR2 (0.43) | LMNAAGTR2 | |
| SCHEMBL3829097 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LMNA | |
| SCHEMBL7265773 | 0.83 | EGFR (0.45) | SIGMAR1ALDH1A1 | |
| SCHEMBL9024007 | 0.78 | NR1D1 (0.39) | AGTR2 | |
| SCHEMBL3827793 | 0.78 | MC4R (0.47) | SIGMAR1ALDH1A1LMNA | |
| SCHEMBL8571007 | 0.76 | PARP1 (0.49) | SIGMAR1AGTR2 | |
| SCHEMBL8571009 | 0.76 | PARP1 (0.49) | SIGMAR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | SIGMAR1 4489/4885ALDH1A1 1990/4885LMNA 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.